News Search Results
Mar 05, 2026, 16:57 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Mar 05, 2026, 16:05 ET INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 05, 2026, 16:01 ET AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Mar 05, 2026, 12:19 ET Rubin Rudman Launches New Hospitality Law Practice Group
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
Mar 05, 2026, 11:16 ET Cultured Meat Market to Reach $6,501.8 million, Globally, by 2033 at 58.5% CAGR: Allied Market Research
environmental and animal welfare concerns, and continuous advancements in cellular agriculture technologies. In addition, expanding investments in food biotechnology, improvements in bioreactor and growth media development, and growing consumer interest in clean-label products are strengthening market demand.
More news about: Allied Market Research
Mar 05, 2026, 10:16 ET Lipid Nanoparticles Market to Reach $3.1 Billion, Globally, by 2033 at 13.1% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/connect-to-analyst/A323703 By end user, the pharmaceutical & biotechnology companies segment held the highest market share in 2023Pharmaceutical and biotechnology companies accounted for the largest share in 2023, supported by the increasing development and
More news about: Allied Market Research
Mar 05, 2026, 10:14 ET BIOMEMORY ACQUIRES THE ASSETS OF CATALOG, BOOSTING ITS AMBITIONS IN DNA DATA STORAGE AND COMPUTING
years of research work in Sorbonne University and CNRS French national labs. It is a leading innovator and market player, at the intersection of biotechnology and information technologies. The company develops IT-friendly Data Storage and cybersecurity solutions, using DNA as the storage media. Solutions
More news about: Biomemory
Mar 05, 2026, 10:00 ET Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout
MISSOULA, Mont., March 5, 2026 /PRNewswire/ -- Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, today announced the appointments of Ferdinand Massari, M.D., as Chief Medical Officer (CMO),
More news about: Inimmune
Mar 05, 2026, 09:30 ET Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales
worldwide."Snook's appointment comes as Slingshot Biosciences experiences rapid adoption of its synthetic cell mimic platform among pharmaceutical companies, biotechnology firms, clinical diagnostics laboratories, and academic research institutions. His leadership will be critical in capitalizing on the growing demand
More news about: Slingshot Biosciences
Mar 05, 2026, 09:30 ET Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales
worldwide."Snook's appointment comes as Slingshot Biosciences experiences rapid adoption of its synthetic cell mimic platform among pharmaceutical companies, biotechnology firms, clinical diagnostics laboratories, and academic research institutions. His leadership will be critical in capitalizing on the growing demand
More news about: Slingshot Biosciences
Mar 05, 2026, 09:28 ET Cerecin Announces TEDx Talk by CEO Dr. Charles Stacey is Now Available Online
DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company developing metabolic drugs for neurological disorders, today announced that Dr. Charles Stacey, Chief Executive Officer of Cerecin, delivered
More news about: Cerecin Inc.
Mar 05, 2026, 09:01 ET More Than Half of GLP-1 Users Reported Seeking Follow-Up Care for Side Effects, Phenomix Sciences Report Finds
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today released new findings from its "2026 State of Obesity Treatment Report: Progress, Gaps, and the Path to Personalized Care" report.
More news about: Phenomix Sciences
Mar 05, 2026, 09:00 ET Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ: ONCY), Vir Biotechnology (NASDAQ: VIR), Iovance Biotherapeutics (NASDAQ: IOVA), C4 Therapeutics (NASDAQ: CCCC), and Immunocore (NASDAQ: IMCR).
More news about: Equity Insider
Mar 05, 2026, 09:00 ET Nicoya Lifesciences Announces Launch of FastHDX™, a Millisecond HDX-MS Platform Aimed to Open New Therapeutic Opportunities
it will significantly expand how we study protein motion, disorder, and mechanism – ultimately unlocking our understanding of complex disease, biotechnology and medicines.""FastHDX is the culmination of nearly a decade of development by the Applied Photophysics team, shaped by deep external expertise
More news about: Nicoya Lifesciences Inc.
Mar 05, 2026, 09:00 ET SkylineDx Launches a Guideline-Informed Risk Assessment Initiative to Support SLNB Decision-Making in Early-Stage Melanoma
www.merlinmelanomatest.comAbout SkylineDxSkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Mar 05, 2026, 08:30 ET Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
decoytx.com.About Decoy Therapeutics Inc. Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Mar 05, 2026, 08:00 ET Therna Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics
ConferenceSAN FRANCISCO, March 5, 2026 /PRNewswire/ -- Therna Biosciences, a biotechnology company pioneering programmable RNA therapeutics, today announced a collaboration with Charles River to advance single-patient RNA medicines for
More news about: Therna Biosciences
Mar 05, 2026, 07:05 ET REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Mar 05, 2026, 07:00 ET Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia
Mass. and COPENHAGEN, Denmark, March 5, 2026 /PRNewswire/ -- Hemab Therapeutics, a late stage clinical biotechnology company developing novel prophylactic therapeutics for serious, underserved coagulation disorders, today announced that the U.S. Food and Drug Administration
More news about: Hemab Therapeutics
Mar 05, 2026, 06:00 ET Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 05, 2026, 01:15 ET New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: F. Hoffman-La Roche AG
Mar 04, 2026, 20:40 ET 以千分之一劑量 CAR-T 實現血液瘤與紅斑狼瘡100%完全緩解，晶泰孵化企業萊芒生物完成近2億元融資，「平價」新型高效細胞療法開啟臨床轉化
Ltd）是一家處於臨床階段的免疫代謝創新藥物研發公司，由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技共同創立。基於免疫代謝重編程（META 10）+前沿人工智能（AI）的創新技術，公司專注於研發代謝增強型腫瘤免疫治療藥物。公司核心技術 META 10 展示出治癒實體腫瘤的巨大潛力，相關成果發表於 Nature、Nature Biotechnology、Nature Immunology 和 Lancet Haematology 等國際頂級學術期刊，並申請了多項 PCT 專利和中國發明專利。2022 年以來，公司累計獲得超 4 億元風險投資和項目資助，榮膺 2025 年全國 「顛覆性技術創新」 大賽最高獎項等數十項生物醫藥領域國家或省市級獎項，併入選國家重點研發計劃「顛覆性技術創新」
More news about: 晶泰科技
Mar 04, 2026, 18:01 ET Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight
This has accelerated its adoption in oncology, immunotherapy, and gene therapy.Increased R&D Investment: Pharmaceutical and biotechnology companies, along with academic institutions, are substantially investing in research to develop next-generation nanotherapeutics and nano-diagnostics.Rising
More news about: DelveInsight Business Research, LLP
Mar 04, 2026, 16:01 ET AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Mar 04, 2026, 13:00 ET Rice-led research to develop first regenerative therapy for lymphedema receives up to $18.2M federal award
RBL LLC biotechnology startup SteerBio to drive clinical development and commercializationHOUSTON, March 4, 2026 /PRNewswire/ --A team of researchers led by Rice University bioengineer Omid Veiseh
More news about: Rice University